Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.45 |
| ▸ | DRD4 | P21917 | 4/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | AGXT | P21549 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3525840 | 1.00 | NAAA (0.50) | NAAASLC6A4SLC6A2SLC6A3DRD4 | |
| Hydrochloric Acid SCHEMBL3526232 | 0.98 | NAAA (0.49) | NAAASLC6A4SLC6A2SLC6A3DRD4 | |
| Hydrochloric Acid SCHEMBL3526231 | 0.98 | NAAA (0.49) | NAAASLC6A4SLC6A2SLC6A3DRD4 | |
| SCHEMBL3520412 | 0.83 | DRD2 (0.57) | NAAASLC6A4SLC6A2SLC6A3DRD2 | |
| SCHEMBL3520414 | 0.83 | DRD2 (0.57) | NAAASLC6A4SLC6A2SLC6A3DRD2 | |
| SCHEMBL12012212 | 0.83 | DRD2 (0.43) | SLC6A4SLC6A2SLC6A3DRD2DRD3 | |
| SCHEMBL12012186 | 0.83 | SLC6A4 (0.56) | NAAASLC6A4SLC6A2SLC6A3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL3519631 | 0.82 | DRD2 (0.43) | SLC6A4SLC6A2SLC6A3DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL3519632 | 0.82 | DRD2 (0.43) | SLC6A4SLC6A2SLC6A3DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL3523794 | 0.82 | DRD2 (0.56) | NAAASLC6A4SLC6A2SLC6A3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2241567-A1 | BICYCLOAMINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-10-20 | — | — | EP | disclosed |
| EP-2241567-A1 | BICYCLOAMINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | NAAA 615/4885SLC6A4 416/4885SLC6A2 333/4885 |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | NAAA 615/4885SLC6A4 416/4885SLC6A2 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.